Lexeo Therapeutics, Inc. Common Stock
NASDAQ Global MarketTotal Valuation
Lexeo Therapeutics, Inc. Common Stock carries a market capitalization of 226.56M, placing it among publicly traded companies globally. Its enterprise value stands at 161.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 226.56M |
| Enterprise Value | 161.49M |
Share Statistics
Lexeo Therapeutics, Inc. Common Stock currently has 78.62M shares outstanding.
| Shares Outstanding | 78.62M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 1.56 |
| P/TBV Ratio | 1.56 |
| P/FCF Ratio | -4.02 |
| P/OCF Ratio | -4.01 |
Financial Position
Lexeo Therapeutics, Inc. Common Stock maintains a current ratio of 13.89, meaning it holds 13.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.90, indicating elevated leverage, while an interest coverage ratio of -584.57 demonstrates limited ability to service its debt obligations.
| Current Ratio | 13.89 |
| Quick Ratio | 13.49 |
| Debt / Equity | 2.90 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | -584.57 |
Financial Efficiency
| Return on Equity (ROE) | -46.76 |
| Return on Assets (ROA) | -40.50 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Lexeo Therapeutics, Inc. Common Stock's stock has declined approximately -70.06508% over the past 52 weeks. The 50-day moving average sits at 4.11, while the 200-day moving average is 5.49.
| Beta (5Y) | N/A |
| 52-Week Price Change | -70.06508% |
| 50-Day Moving Average | 4.11 |
| 200-Day Moving Average | 5.49 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -92.95M, while operating income came in at -95.12M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -95.12M |
| Pretax Income | -87.26M |
| Net Income | -87.26M |
| EBITDA | -92.95M |
| EBIT | -95.12M |
| Earnings Per Share (EPS) | -1.15 |
Balance Sheet
Lexeo Therapeutics, Inc. Common Stock holds 211.70M in cash and equivalents against 6.81M in total debt, resulting in a net debt position of -92.83M. Total book value stands at 235.06M, with working capital of 202.22M providing operational flexibility.
| Cash & Cash Equivalents | 211.70M |
| Total Debt | 6.81M |
| Net Debt | -92.83M |
| Equity (Book Value) | 235.06M |
| Book Value Per Share | 2.99 |
| Working Capital | 202.22M |
Cash Flow
Lexeo Therapeutics, Inc. Common Stock produced -88.37M in operating cash flow over the past twelve months. After subtracting -331,000.00 in capital expenditures, free cash flow totaled -88.70M - equivalent to -1.17 per share.
| Operating Cash Flow | -88.37M |
| Capital Expenditures | -331,000.00 |
| Free Cash Flow | -88.70M |
| FCF Per Share | -1.17 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -46.58 |
| FCF Yield | -24.85 |
Scores
Lexeo Therapeutics, Inc. Common Stock posts an Altman Z-Score of 8.46, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 8.46 |